Summary
This prediction ended on 16.10.17 with a price of €18.28. The prediction had a final performance of 13.79%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ablynx NV | - | - | - | - |
| iShares Core DAX® | 3.023% | 2.202% | 14.664% | 48.878% |
| iShares Nasdaq 100 | 3.561% | 1.325% | 31.410% | 83.744% |
| iShares Nikkei 225® | 6.618% | 5.707% | 49.420% | 60.392% |
| iShares S&P 500 | 2.635% | 1.008% | 25.116% | 61.272% |
Comments by melinda for this prediction
In the thread Ablynx NV diskutieren
Ablynx ( ABLYF.PK ) Montag angekündigt , positive Ergebnisse auf die Grundlinie der Studie der Phase III mit HERCULES caplacizumab, Purpura zur Behandlung von thromboembolischen thrombactique thromboembolischen oder thrombotischen ATTP entwickelt.